


Novel antibodies for combating Alzheimer's and Parkinson's disease

3 December 2012



Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study. Credit: Rensselaer/Tessier

Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.

The onset of these devastating diseases is associated with the inappropriate clumping of proteins into particles that are harmful to cells in the brain (Alzheimer's disease and Parkinson's disease) and [pancreas \(Type 2 diabetes\)](#). [Antibodies](#), which are commonly used by the immune system to target foreign invaders such as bacteria and viruses, are promising weapons for preventing the formation of [toxic protein](#) particles. A limitation of conventional antibodies, however, is that high concentrations are required to completely inhibit the formation of toxic protein particles in

Alzheimer's, Parkinson's, and other disorders.

To address this limitation, a team of researchers led by Rensselaer Professor Peter Tessier has developed a new process for creating antibodies that potentially inhibit formation of toxic protein particles. Conventional antibodies typically bind to one or two [target proteins](#) per antibody. Antibodies created using Tessier's method, however, bind to 10 proteins per antibody. The increased potency enables the novel antibodies to prevent the formation of toxic protein particles at unusually low concentrations. This is an important step toward creating new therapeutic molecules for preventing diseases such as Alzheimer's and Parkinson's.

"It is extremely difficult to get antibodies into the brain. Less than 5 percent of an injection of antibodies into a patient's [blood stream](#) will enter the brain. Therefore, we need to make antibodies as potent as possible so the small fraction that does enter the brain will completely prevent formation of toxic protein particles linked to Alzheimer's and Parkinson's disease," said Tessier, assistant professor in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer. "Our strategy for designing antibody inhibitors exploits the same molecular interactions that cause toxic particle formation, and the resulting antibodies are more potent inhibitors than antibodies generated by the immune system."

More information: Results of the new study, titled "Rational design of potent domain antibody inhibitors of amyloid fibril assembly," were published online last week by the journal *Proceedings of the National Academy of Sciences (PNAS)*. The study may be viewed at: www.pnas.org/content/early/2012/12/03/1208797109.abstract

Provided by Rensselaer Polytechnic Institute

APA citation: Novel antibodies for combating Alzheimer's and Parkinson's disease (2012, December 3) retrieved 27 January 2021 from <https://medicalxpress.com/news/2012-12-antibodies-combating-alzheimer-parkinson-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.